Pacific Biosciences Posts $0.12 Q1 Loss, Revenues Miss Estimates
Pacific Biosciences posted a first-quarter loss of $0.12 per share, narrower than last year's $0.15 loss and outperformed the consensus loss estimate of $0.17 per share. First-quarter revenue fell short of analyst forecasts, extending a trend of underwhelming top-line growth.
1. First-Quarter EPS
Pacific Biosciences reported a GAAP loss of $0.12 per share for the quarter ended March 31, 2026, beating the consensus loss estimate of $0.17 per share. This represents an improvement from the $0.15-per-share loss logged in the same quarter a year earlier.
2. Revenue Performance
The company's first-quarter revenue fell below analyst forecasts, marking another quarter of missed top-line expectations. No detailed revenue figures were provided in the earnings announcement.
3. Year-over-Year Improvement
The $0.03-per-share reduction in the quarterly loss compared to Q1 2025 reflects a narrowing of the company’s deficit, although sustained profitability will depend on reversing the revenue shortfall.